Dampened Inflammation and Improved Survival After CXCL5 Administration in Murine Lupus via Myeloid and Neutrophil Pathways
Arthritis & Rheumatology · 2023
DOI: 10.1002/art.42383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von Xiubo Fan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Translational Research, Singapore General Hospital, and SingHealth Duke-NUS Medicine Academic Clinical Programme, Duke-NUS Med…. Hauptthemen laut MEDLINE: Lupus Nephritis, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Medical Research Council, SingHealth Foundation, Singapore General Hospital.
Abstract (Originalsprache)
Objective
To determine the efficacy of CXCL5 administration in lupus‐prone MRL/ lpr (Fas lpr ) mice and elucidate its working mechanisms.
Methods
CXCL5 expression in blood (obtained from SLE patients and Fas lpr mice) and major internal organs (obtained from Fas lpr mice) was examined by Luminex, real‐time polymerase chain reaction, and immunofluorescent staining analyses. Pharmacokinetic studies were performed in Fas lpr mice and healthy Institute of Cancer Research mice. Efficacy of CXCL5 administration was demonstrated in Fas lpr mice, and the working mechanism of CXCL5 treatment was elucidated by flow cytometry, Luminex, and RNA sequencing.
Results
In SLE patients, serum CXCL5 levels were significantly lower than in healthy individuals ( P < 0.0001) and negatively correlated with disease activity ( P = 0.004). In Fas lpr mice, disease severity progressed with age and was negatively associated with plasma CXCL5 levels. Intravenous administration of CXCL5 to Fas lpr mice restored endogenous circulatory CXCL5, improved mice survival, and reduced anti–double‐stranded DNA antibodies, proteinuria, lupus nephritis activity and chronicity indices, renal complements, and neutrophil extracellular traps over short‐term (10 weeks) and long‐term (2 years) time periods. In vitro and in vivo assays demonstrated that CXCL5 dictated neutrophil trafficking and suppressed neutrophil activation, degranulation, proliferation, and renal infiltration. Renal and splenic RNA sequencing further showed that CXCL5‐mediated immunomodulation occurred by promoting energy production in renal‐infiltrated immune cells, activating certain T cells, and reducing tissue fibrosis, granulocyte extravasation, complement components, and interferons. Further factorial design results indicated that CXCL5 appears to enhance host tolerability to cyclophosphamide in vulnerable individuals.
Conclusion
We found that serum CXCL5 levels were significantly lower in SLE patients than in healthy individuals and were negatively correlated with disease activity. By administering CXCL5 intravenously in a mouse model of lupus, mouse survival improved, and indices of disease activity reduced significantly. Taken together, these findings indicate CXCL5 administration may represent a novel myeloid/neutrophil‐targeting therapy for SLE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Clinical Translational Research, Singapore General Hospital, and SingHealth Duke-NUS Medicine Academic Clinical Programme, Duke-NUS Medical School, Singapore.
- Department of Rheumatology and Immunology, Singapore General Hospital, and SingHealth Duke-NUS Medicine Academic Clinical Programme, Duke-NUS Medical School, Singapore.
- Department of Clinical Translational Research, Singapore General Hospital.
- Single-cell Computational Immunology, Singapore Immunology Network, Singapore.
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore.
- Department of Clinical Translational Research, Singapore General Hospital, and Critical Analytics for Manufacturing Personalized Medicine, SMART, Singapore.
ORCID-Profile: Xiubo Fan, Chin Teck Ng, Andrea Low
Förderung
- National Medical Research Council
- SingHealth Foundation
- Singapore General Hospital
Zitieren
APA
Fan, X., Ng, C. T., Guo, D., Lim, F., Tan, J. C., Law, A., Goh, L. H., Poon, Z. Y., Cheung, A., Kong, S. L., Tan, M., Li, S., Loh, A., James, A., Lim, T., Chen, J., Thumboo, J., Hwang, W., & Low, A. (2023). Dampened Inflammation and Improved Survival After CXCL5 Administration in Murine Lupus via Myeloid and Neutrophil Pathways. Arthritis & Rheumatology. https://doi.org/10.1002/art.42383
Vancouver
Fan X, Ng CT, Guo D, Lim F, Tan JC, Law A, et al. Dampened Inflammation and Improved Survival After CXCL5 Administration in Murine Lupus via Myeloid and Neutrophil Pathways. Arthritis & Rheumatology. 2023. doi:10.1002/art.42383
BibTeX
@article{Fan2023,
author = {Fan, Xiubo and Ng, Chin Teck and Guo, Dianyang and Lim, Frances and Tan, Jia Chi and Law, Annie and Goh, Lim Hee and Poon, Zhi Yong and Cheung, Alice and Kong, Say Li and Tan, Michelle and Li, Shang and Loh, Alwin and James, Anne and Lim, Tony and Chen, Jinmiao and Thumboo, Julian and Hwang, William and Low, Andrea},
title = {Dampened Inflammation and Improved Survival After CXCL5 Administration in Murine Lupus via Myeloid and Neutrophil Pathways},
journal = {Arthritis & Rheumatology},
year = {2023},
doi = {10.1002/art.42383}
}
EUVIMED